Juvena Therapeutics

NEWS
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Juvena Therapeutics pulled in $41 million in Series A financing to advance research into the therapeutic potential of secreted proteins to target chronic and age-related diseases.
IN THE PRESS
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg